Heterogeneity of Response to Methylphenidate in Apathetic Patients in the ADMET 2 Trial.

ABSTRACT:

Objective

The Apathy in Dementia Methylphenidate Trial 2 (ADMET 2) found that methylphenidate was effective in treating apathy with a small-to-medium effect size but showed heterogeneity in response. We assessed clinical predictors of response to help determine individual likelihood of treatment benefit from methylphenidate.

Design

Univariate and multivariate analyses of 22 clinical predictors of response chosen a priori.

Setting

Data from the ADMET 2 randomized, placebo controlled multi-center clinical trial.

Participants

Alzheimer's disease patients with clinically significant apathy.

Measurements

Apathy assessed with the Neuropsychiatric Inventory apathy domain (NPI-A).

Results

In total, 177 participants (67% male, mean [SD] age 76.4 [7.9], min

SUBMITTER: Lanctot KL 

PROVIDER: S-EPMC10765607 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature